Telisotuzumab vedotin explained

Telisotuzumab vedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer.^{[1] [2] [3] [4] [5]}

Notes and References

1. Camidge . D. Ross . Barlesi . Fabrice . Goldman . Jonathan W. . Morgensztern . Daniel . Heist . Rebecca . Vokes . Everett . Spira . Alex . Angevin . Eric . Su . Wu-Chou . Hong . David S. . Strickler . John H. . Motwani . Monica . Dunbar . Martin . Parikh . Apurvasena . Noon . Elysa . Blot . Vincent . Wu . Jun . Kelly . Karen . Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer . Journal of Clinical Oncology . 10 February 2023 . 41 . 5 . 1105–1115 . 10.1200/JCO.22.00739 . 36288547 . 0732-183X. 9928626 .
2. Fujiwara . Yutaka . Kenmotsu . Hirotsugu . Yamamoto . Noboru . Shimizu . Toshio . Yonemori . Kan . Ocampo . Christopher . Parikh . Apurvasena . Okubo . Sumiko . Fukasawa . Kazuteru . Murakami . Haruyasu . Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors . Cancer Medicine . April 2021 . 10 . 7 . 2350–2358 . 10.1002/cam4.3815 . 33675179 . en . 2045-7634. 7982615 .
3. Camidge . D. Ross . Barlesi . Fabrice . Goldman . Jonathan W. . Morgensztern . Daniel . Heist . Rebecca . Vokes . Everett . Angevin . Eric . Hong . David S. . Rybkin . Igor I. . Barve . Minal . Bauer . Todd M. . Delmonte . Angelo . Dunbar . Martin . Motwani . Monica . Parikh . Apurvasena . Noon . Elysa . Wu . Jun . Blot . Vincent . Kelly . Karen . A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC . JTO Clinical and Research Reports . January 2022 . 3 . 1 . 100262 . 10.1016/j.jtocrr.2021.100262. 35005654 . 8717236 .
4. Waqar . Saiama N. . Redman . Mary W. . Arnold . Susanne M. . Hirsch . Fred R. . Mack . Philip C. . Schwartz . Lawrence H. . Gandara . David R. . Stinchcombe . Thomas E. . Leighl . Natasha B. . Ramalingam . Suresh S. . Tanna . Saloni H. . Raddin . Ryan S. . Minichiello . Katherine . Bradley . Jeffrey D. . Kelly . Karen . Herbst . Roy S. . Papadimitrakopoulou . Vassiliki A. . A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753) . Clinical Lung Cancer . 1 May 2021 . 22 . 3 . 170–177 . 10.1016/j.cllc.2020.09.013 . 33221175 . 1525-7304. 8044254 .
5. Strickler . John H. . Weekes . Colin D. . Nemunaitis . John . Ramanathan . Ramesh K. . Heist . Rebecca S. . Morgensztern . Daniel . Angevin . Eric . Bauer . Todd M. . Yue . Huibin . Motwani . Monica . Parikh . Apurvasena . Reilly . Edward B. . Afar . Daniel . Naumovski . Louie . Kelly . Karen . First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors . Journal of Clinical Oncology . 20 November 2018 . 36 . 33 . 3298–3306 . 10.1200/jco.2018.78.7697. free . 30285518 .